BioXcel Therapeutics Files 8-K on Financials
Ticker: BTAI · Form: 8-K · Filed: Mar 12, 2024 · CIK: 1720893
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
BioXcel Therapeutics dropped an 8-K detailing their financial condition and operations.
AI Summary
BioXcel Therapeutics, Inc. filed an 8-K on March 12, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial status. The company is incorporated in Delaware and headquartered in New Haven, CT.
Why It Matters
This filing provides investors with crucial, up-to-date financial information and operational status for BioXcel Therapeutics, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any immediately alarming or significant new risks.
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Registrant
- March 12, 2024 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- New Haven, CT (location) — Principal Executive Offices
FAQ
What specific financial statements are included in this 8-K filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific details of these statements are not provided in the provided text.
What is the primary purpose of this 8-K filing?
The primary purpose is to report on the 'Results of Operations and Financial Condition' of BioXcel Therapeutics, Inc.
When was the earliest event reported in this filing?
The earliest event reported is dated March 12, 2024.
What is BioXcel Therapeutics, Inc.'s standard industrial classification?
BioXcel Therapeutics, Inc.'s standard industrial classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.
What is the business phone number for BioXcel Therapeutics, Inc.?
The business phone number for BioXcel Therapeutics, Inc. is (475) 238-6837.
Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-03-12 07:15:26
Key Financial Figures
- $0.001 B — h registered Common Stock, par value $0.001 BTAI The Nasdaq Capital Market Indic
Filing Documents
- tm248359d1_8k.htm (8-K) — 26KB
- tm248359d1_ex99-1.htm (EX-99.1) — 80KB
- 0001104659-24-033247.txt ( ) — 288KB
- btai-20240312.xsd (EX-101.SCH) — 3KB
- btai-20240312_lab.xml (EX-101.LAB) — 33KB
- btai-20240312_pre.xml (EX-101.PRE) — 22KB
- tm248359d1_8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operations and Financial Condition. On March 12, 2024, BioXcel Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three months and year ended December 31, 2023 and provided a business update. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits. Exhibit No. Description 99.1 Press release, dated March 12, 2024 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 12, 2024 BIOXCEL THERAPEUTICS, INC. /s/ Richard Steinhart By: Richard Steinhart Title: Chief Financial Officer